Health Discovery Corporation (OTCBB: HDVY) is pleased to announce that Thomas L. Gallagher has been appointed by the Board of Directors as President, Chief Operating Officer and General Counsel effective immediately.

Mr. Gallagher started at Health Discovery Corporation in late November 2009, as Executive Vice President and Managing Director, Global IP Strategies. Since August 9, 2010, Thomas L. Gallagher assumed the duties of President, General Counsel and Principal Financial Officer, in addition to his current duties.

“Tom has provided outstanding leadership this past year across our entire business,” said Stephen D. Barnhill, M.D., Chairman and CEO of Health Discovery Corporation. “He possesses a unique combination of strong execution skills, solid business and legal judgment, and a keen sense of new business development and strategy,” said Dr. Barnhill.

“It’s been an exciting year for Health Discovery Corporation and I’ve enjoyed immensely working closely with Dr. Barnhill, the Board of Directors and our colleagues to help drive our business to new levels of success,” Mr. Gallagher said.

On October 20, 2010, the Board of Directors also approved the grant to Mr. Gallagher of 2,500,000 options to purchase common stock. The options are exercisable immediately at an exercise price of $0.19 per share (the closing price on the grant date) and expire ten years after the grant date. For calendar year 2010, Mr. Gallagher will receive a base salary of $120,000 and will be eligible to receive a bonus of $120,000. The Company will record a charge of $357,798 in the fourth quarter with respect to the option grant. For calendar year 2011, Mr. Gallagher and the Board of Directors expect to finalize his compensation package by year-end 2010.

On October 21, 2010, the Company held its annual meeting of shareholders. The results were certified by Corporate Stock Transfer, Inc., the Company’s transfer agent. At the meeting, the shareholders elected the following directors by the vote shown:






Stephen D. Barnhill, M.D. 76,206,370 3,180,924 78,170,700
D. Paul Graham 78,550,012 837,282 78,170,700
Joseph McKenzie, D.V.M. 78,586,687 800,607 78,170,700
Curtis G. Anderson 78,532,285 855,009 78,170,700

Broker non-votes occur when shares held by a broker are not voted with respect to a particular proposal because the broker has not received voting instructions from the beneficial owner and the broker lacks discretionary voting power to vote such shares. Under New York Stock Exchange Rules, a broker does not have discretionary authority to vote in the election of directors absent instructions from the beneficial owner.

In addition, the shareholders ratified the appointment by the Audit Committee of Hancock Askew & Co., LLP, as the Company's independent auditors for the fiscal year 2010 by the vote shown:

Votes for:   154,545,998
Votes against: 921,581
Abstaining: 2,090,415

About Health Discovery Corporation

Health Discovery Corporation is a molecular diagnostics company that uses advanced mathematical techniques to analyze large amounts of data to uncover patterns that might otherwise be undetectable. It operates primarily in the emerging field of personalized medicine where such tools are critical to scientific discovery. Its primary business consists of licensing its intellectual property and developing its own product line of biomarker-based diagnostic tests that include human genes and genetic variations, as well as gene, protein, and metabolic expression differences and image analysis in digital pathology and radiology. For more information, see

Forward-Looking Statements

This document contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, the accuracy of which is necessarily subject to risks and uncertainties, including, without limitation, statements regarding future performance, opportunities and investments, and anticipated results in general. From time to time the Company may make other forward-looking statements relating to other matters, including without limitation, commercialization plans and strategic partnerships. Actual results may differ materially due to a variety of factors, including, among other things, the acceptance of our approach to applying mathematics computer science and physics into the disciplines of biology, organic chemistry and medicine and our products and technologies associated with those approaches, the ability to develop or commercialize new drugs, therapies or other products based on our approaches, and other factors set forth from time to time in the Company’s Securities and Exchange Commission filings.

All forward-looking statements and cautionary statements included in this document are made as of the date hereof based on information available to the Company as of the date hereof, and the Company assumes no obligation to update any forward-looking statement or cautionary statement.

Copyright Business Wire 2010